Serious infections in patients with VEXAS syndrome : data from the French VEXAS registry
© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ..
INTRODUCTION: Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is an acquired autoinflammatory monogenic disease with a poor prognosis whose determinants are not well understood. We aimed to describe serious infectious complications and their potential risk factors.
METHODS: Retrospective multicentre study including patients with VEXAS syndrome from the French VEXAS Registry. Episodes of serious infections were described, and their risk factors were analysed using multivariable Cox proportional hazards models.
RESULTS: Seventy-four patients with 133 serious infections were included. The most common sites of infection were lung (59%), skin (10%) and urinary tract (9%). Microbiological confirmation was obtained in 76%: 52% bacterial, 30% viral, 15% fungal and 3% mycobacterial. Among the pulmonary infections, the main pathogens were SARS-CoV-2 (28%), Legionella pneumophila (21%) and Pneumocystis jirovecii (19%). Sixteen per cent of severe infections occurred without any immunosuppressive treatment and with a daily glucocorticoid dose ≤10 mg. In multivariate analysis, age >75 years (HR (95% CI) 1.81 (1.02 to 3.24)), p.Met41Val mutation (2.29 (1.10 to 5.10)) and arthralgia (2.14 (1.18 to 3.52)) were associated with the risk of serious infections. JAK inhibitors were most associated with serious infections (3.84 (1.89 to 7.81)) compared with biologics and azacitidine. After a median follow-up of 4.4 (2.5-7.7) years, 27 (36%) patients died, including 15 (56%) due to serious infections.
CONCLUSION: VEXAS syndrome is associated with a high incidence of serious infections, especially in older patients carrying the p.Met41Val mutation and treated with JAK inhibitors. The high frequency of atypical infections, especially in patients without treatment, may indicate an intrinsic immunodeficiency.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:83 |
|---|---|
| Enthalten in: |
Annals of the rheumatic diseases - 83(2024), 3 vom: 15. Feb., Seite 372-381 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
de Valence, Benjamin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Azacitidine |
|---|
| Anmerkungen: |
Date Completed 19.02.2024 Date Revised 12.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/ard-2023-224819 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365623210 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365623210 | ||
| 003 | DE-627 | ||
| 005 | 20240312233438.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/ard-2023-224819 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1324.xml |
| 035 | |a (DE-627)NLM365623210 | ||
| 035 | |a (NLM)38071510 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a de Valence, Benjamin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serious infections in patients with VEXAS syndrome |b data from the French VEXAS registry |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.02.2024 | ||
| 500 | |a Date Revised 12.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a INTRODUCTION: Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is an acquired autoinflammatory monogenic disease with a poor prognosis whose determinants are not well understood. We aimed to describe serious infectious complications and their potential risk factors | ||
| 520 | |a METHODS: Retrospective multicentre study including patients with VEXAS syndrome from the French VEXAS Registry. Episodes of serious infections were described, and their risk factors were analysed using multivariable Cox proportional hazards models | ||
| 520 | |a RESULTS: Seventy-four patients with 133 serious infections were included. The most common sites of infection were lung (59%), skin (10%) and urinary tract (9%). Microbiological confirmation was obtained in 76%: 52% bacterial, 30% viral, 15% fungal and 3% mycobacterial. Among the pulmonary infections, the main pathogens were SARS-CoV-2 (28%), Legionella pneumophila (21%) and Pneumocystis jirovecii (19%). Sixteen per cent of severe infections occurred without any immunosuppressive treatment and with a daily glucocorticoid dose ≤10 mg. In multivariate analysis, age >75 years (HR (95% CI) 1.81 (1.02 to 3.24)), p.Met41Val mutation (2.29 (1.10 to 5.10)) and arthralgia (2.14 (1.18 to 3.52)) were associated with the risk of serious infections. JAK inhibitors were most associated with serious infections (3.84 (1.89 to 7.81)) compared with biologics and azacitidine. After a median follow-up of 4.4 (2.5-7.7) years, 27 (36%) patients died, including 15 (56%) due to serious infections | ||
| 520 | |a CONCLUSION: VEXAS syndrome is associated with a high incidence of serious infections, especially in older patients carrying the p.Met41Val mutation and treated with JAK inhibitors. The high frequency of atypical infections, especially in patients without treatment, may indicate an intrinsic immunodeficiency | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Glucocorticoids | |
| 650 | 4 | |a Immune System Diseases | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Therapeutics | |
| 650 | 4 | |a Tumor Necrosis Factor Inhibitors | |
| 650 | 7 | |a Azacitidine |2 NLM | |
| 650 | 7 | |a M801H13NRU |2 NLM | |
| 650 | 7 | |a Janus Kinase Inhibitors |2 NLM | |
| 700 | 1 | |a Delaune, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Yann |e verfasserin |4 aut | |
| 700 | 1 | |a Jachiet, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Heiblig, Mael |e verfasserin |4 aut | |
| 700 | 1 | |a Jean, Alexis |e verfasserin |4 aut | |
| 700 | 1 | |a Riescher Tuczkiewicz, Stanislas |e verfasserin |4 aut | |
| 700 | 1 | |a Henneton, Pierrick |e verfasserin |4 aut | |
| 700 | 1 | |a Guilpain, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Schleinitz, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Le Guenno, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Lobbes, Hervé |e verfasserin |4 aut | |
| 700 | 1 | |a Lacombe, Valentin |e verfasserin |4 aut | |
| 700 | 1 | |a Ardois, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Lazaro, Estibaliz |e verfasserin |4 aut | |
| 700 | 1 | |a Langlois, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Outh, Roderau |e verfasserin |4 aut | |
| 700 | 1 | |a Vinit, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Martellosio, Jean-Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Decker, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Moulinet, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Dieudonné, Yannick |e verfasserin |4 aut | |
| 700 | 1 | |a Bigot, Adrien |e verfasserin |4 aut | |
| 700 | 1 | |a Terriou, Louis |e verfasserin |4 aut | |
| 700 | 1 | |a Vlakos, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a de Maleprade, Baptiste |e verfasserin |4 aut | |
| 700 | 1 | |a Denis, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Broner, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Kostine, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Humbert, Sebastien |e verfasserin |4 aut | |
| 700 | 1 | |a Lifermann, Francois |e verfasserin |4 aut | |
| 700 | 1 | |a Samson, Maxime |e verfasserin |4 aut | |
| 700 | 1 | |a Pechuzal, Susann |e verfasserin |4 aut | |
| 700 | 1 | |a Aouba, Achille |e verfasserin |4 aut | |
| 700 | 1 | |a Kosmider, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Dion, Jeremie |e verfasserin |4 aut | |
| 700 | 1 | |a Grosleron, Sylvie |e verfasserin |4 aut | |
| 700 | 1 | |a Bourguiba, Rim |e verfasserin |4 aut | |
| 700 | 1 | |a Terrier, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Georgin-Lavialle, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Fain, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Mekinian, Arsène |e verfasserin |4 aut | |
| 700 | 1 | |a Morgand, Marjolaine |e verfasserin |4 aut | |
| 700 | 1 | |a Comont, Thibault |e verfasserin |4 aut | |
| 700 | 1 | |a Hadjadj, Jerome |e verfasserin |4 aut | |
| 700 | 0 | |a French VEXAS Group |e verfasserin |4 aut | |
| 700 | 1 | |a Melki, Isabelle |e investigator |4 oth | |
| 700 | 1 | |a Fenaux, Pierre |e investigator |4 oth | |
| 700 | 1 | |a Ades, Lionel |e investigator |4 oth | |
| 700 | 1 | |a Audemard, Alexandra |e investigator |4 oth | |
| 700 | 1 | |a Ebbo, Mikael |e investigator |4 oth | |
| 700 | 1 | |a Jamilloux, Yvan |e investigator |4 oth | |
| 700 | 1 | |a Rauzy, Odile Beyne |e investigator |4 oth | |
| 700 | 1 | |a Belot, Alexandre |e investigator |4 oth | |
| 700 | 1 | |a Borie, Raphaël |e investigator |4 oth | |
| 700 | 1 | |a Mathian, Alexis |e investigator |4 oth | |
| 700 | 1 | |a Arnaud, Laurent |e investigator |4 oth | |
| 700 | 1 | |a Chasset, François |e investigator |4 oth | |
| 700 | 1 | |a Bouaziz, Jean-David |e investigator |4 oth | |
| 700 | 1 | |a Sujobert, Pierre |e investigator |4 oth | |
| 700 | 1 | |a Benhamou, Ygal |e investigator |4 oth | |
| 700 | 1 | |a Sauvetre, Gaetan |e investigator |4 oth | |
| 700 | 1 | |a El-Karoui, Khalil |e investigator |4 oth | |
| 700 | 1 | |a Rodrigues, François |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of the rheumatic diseases |d 1939 |g 83(2024), 3 vom: 15. Feb., Seite 372-381 |w (DE-627)NLM000174114 |x 1468-2060 |7 nnns |
| 773 | 1 | 8 | |g volume:83 |g year:2024 |g number:3 |g day:15 |g month:02 |g pages:372-381 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/ard-2023-224819 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 83 |j 2024 |e 3 |b 15 |c 02 |h 372-381 | ||